GSK president acquires 9.324 notional ADS

GSK plc disclosed that Maya Martinez-Davis, President, acquired 9.324 notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account on October 22, 2026, at a reported price of $51.2100 per ADS.

Rhea-AI Filing Summary

GSK plc disclosed that Maya Martinez-Davis, President, acquired 9.324 notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan account on October 22, 2026, at a reported price of $51.2100 per ADS. The transaction was reported as a single transaction on the New York Stock Exchange.

Key Figures

Transaction volume: 9.324 notional ADS Reported price: $51.2100 per ADS Transaction date: October 22, 2026

3 metrics

Transaction volume 9.324 notional ADS Maya Martinez-Davis’s reported acquisition

Reported price $51.2100 per ADS Maya Martinez-Davis’s reported acquisition

Transaction date October 22, 2026 Date of the reported acquisition

Key Terms

American Depositary Shares (ADS), notional ADS, person closely associated (PCA)

3 terms

American Depositary Shares (ADS) financial

"Description of the financial instrument | American Depositary Shares (‘ADS’)"

American depositary shares (ADS) are a way for investors in the United States to buy shares of foreign companies without dealing with the complexities of international markets. They represent ownership in a foreign company's stock and are traded on U.S. exchanges, making it easier and more convenient for Americans to invest internationally. ADSs allow investors to diversify their portfolios with foreign companies while using familiar trading platforms.

notional ADS financial

"Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account"

person closely associated (PCA) regulatory

"Details of PDMR/person closely associated with them (‘PCA’)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GSK ADS did Maya Martinez-Davis acquire, and at what price?

Maya Martinez-Davis acquired 9.324 notional ADS at $51.2100 per ADS on October 22, 2026, within her GSK Executive Supplemental Savings Plan account.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 12:05 PM EDT Accepted by SEC EDGAR 10/26/2026 - 12:05 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		$51.2100	9.324
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-10-22
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: October 26, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc